Overview

Calaspargase Pegol in Adults With ALL

Status:
Recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company